Influsplit Tetra

B/Phuket/3073/2013-like Virus, the active ingredient in Influsplit Tetra, is a vaccine presented as a split‑virion formulation for intramuscular use. It helps prevent influenza infection caused by the B/Phuket/3073/2013-like and B/Austria/1359417/202 strains and contributes to seasonal influenza prophylaxis in the general population.

GNH USA supplies Influsplit Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Influsplit Tetra is a quadrivalent influenza vaccine used to protect against influenza B virus infections.

Prevention of influenza B infection (B/Phuket/3073/2013-like): reduces incidence of illness caused by this strain. Prevention of influenza B infection (B/Austria/1359417/202): reduces incidence of illness caused by this strain. Seasonal influenza prophylaxis: provides broader protection against circulating influenza viruses during the flu season.

Like other influenza vaccines, Influsplit Tetra may be associated with local and systemic reactions.

Common Side Effects: - Pain at injection site: mild to moderate soreness. - Redness or swelling at injection site. - Low‑grade fever. - Headache. - Muscle aches. - Fatigue.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder. - Seizures: especially in children with a history of febrile seizures. - High‑grade fever >39°C. - Persistent vomiting. - Severe local reaction with extensive swelling.

Before administering Influsplit Tetra, consider the following precautions. - Contraindication: severe allergic reaction to any component of the vaccine: do not vaccinate. - History of Guillain‑Barré syndrome: evaluate risk versus benefit before use. - Acute moderate or severe illness: postpone vaccination until recovery. - Pregnancy: vaccine may be administered if benefits outweigh potential risks; consult healthcare provider. - Immunocompromised patients: vaccine may be less effective; monitor response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influsplit Tetra can interact with other vaccines or immunomodulatory agents.

Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration within 4 weeks to prevent interference. - Immunoglobulin therapy: may reduce vaccine efficacy if given within 2 weeks before or after vaccination.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): may blunt antibody response if taken prophylactically; use only for symptomatic relief. - Corticosteroids (systemic): may diminish immune response; assess timing. - Antiviral medications (oseltamivir): generally safe but monitor for any reduced immunogenicity.